Evan Jacob Lipson MD

Melanoma

Associate Professor of Oncology, Johns Hopkins University School of Medicine

201 North Broadway StreetViragh BLDG 5th FLBaltimore, MD 21287
Phone+1 410-955-8964
Fax+1 410-367-2194

Dr. Lipson is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lipson's full profile Already have an account?

Summary

Evan Lipson, MD is an Oncologist based in Baltimore, MD, with a subspecialty in Melanoma. He completed his fellowship and residency in Hematology and Medical Oncology at Johns Hopkins University and is a graduate of Icahn School of Medicine at Mount Sinai. Dr. Lipson has a proven experience in dealing with skin cancer, mohs micrographic surgery, melanoma and related malignancies and has a number of significant publications to his name. He has led clinical trials on immunotherapy and related treatments for unmanageable or metastatic skin cancers. He earned the CMS Meaningful Use Stage 1 Certification from EpicCare Ambulatory EMR, Epic Systems Corporation in 2013-2014.

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2008 - 2011
Johns Hopkins UniversityResidency, Internal Medicine, 2005 - 2008
Icahn School of Medicine at Mount SinaiClass of 2005

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2022 - Present
DC State Medical License 2012 - 2028
MD State Medical License 2008 - 2028
PA State Medical License 2024 - 2026
VA State Medical License 2021 - 2026
DE State Medical License 2022 - 2023
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014, 2016-2017

Clinical Trials

Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma Start of enrollment: 2018 Nov 27
RECRUITING
PHASE2
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Start of enrollment: 2019 Nov 08
ACTIVE_NOT_RECRUITING
PHASE1
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Start of enrollment: 2024 Jul 24
RECRUITING
PHASE1, PHASE2
Roles: Contact, Principal Investigator

Publications & Presentations

PubMed

Summary recommendations from the NCI clinical trials planning meeting (CTPM) on advanced cutaneous squamous cell carcinoma in immunosuppressed patients.
Shlomo A Koyfman, Julie E Bauman, Mehrdad Mohseni, Moran Amit, Darshana M Dadhania
Journal of the National Cancer Institute. 2026-07-21
Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumors.
Howard L Li, Soren Charmsaz, Chester Kao, Carlotta Pazzi, Madelena Brancati
Cancer Immunology Research. 2026-06-26
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.
James William Smithy, Allison Betof, Sebastian Klobuch, Troels Holz Borch, Hannah L Kalvin
Journal for Immunotherapy of Cancer. 2026-06-25

Journal Articles

From Validity to Clinical Utility: The Influence of Circulating Tumor DNA on Melanoma Patient Management in a Real‐World Setting
Karen B Bleich, William H Sharfman, Steven P Rowe, Evan J Lipson, Megan D Schollenberger, Molecular Oncology
Nodular Regenerative Hyperplasia Associated with Immune Checkpoint Blockade
Evan J Lipson, Michael I Brener, Jaclyn LoPiccolo, James P Hamilton, Hepatology

Press Mentions

Toxic Trade-OffsMarch 16th, 2023
Evan Lipson, MD, on Nivolumab plus Relatlimab for Advanced MelanomaJuly 14th, 2022
ASCO: Nivolumab, Relatlimab Combo Slows Advanced MelanomaMay 30th, 2021